Factor IX inhibitors and anaphylaxis in hemophilia B

American Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 1, 1997, Pages 23-27

  Warrier, Indira ^a   Ewenstein, Bruce M ^b   Koerper, Marion A ^c   Shapiro, Amy ^d   Key, Nigel ^e   DiMichele, Donna ^f   Miller, Robert T ^g   Pasi, John ^h   Rivard, Georges E ⁱ   Sommer, Steve S ^j   Katz, Jacob ^k   Bergmann, Frauke ^l   Ljung, Rolf ^m   Petrini, Pia ⁿ   Lusher, Jeanne M ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RILEY HOSPITAL FOR CHILDREN   (United States)

^e UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^f WEILL CORNELL MEDICAL CENTER   (United States)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

^h ROYAL FREE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF MONTREAL   (Canada)

^j MAYO CLINIC   (United States)

^k Medical School of Hannover ^*  (United States)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m LUND UNIVERSITY   (Sweden)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Anaphylaxis; Factor IX gene deletion; Factor IX inhibitor; Hemophilia B; Nephrotic syndrome; Recombinant factor VIIa

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; STEROID;

ANAPHYLAXIS; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; DESENSITIZATION; GENE DELETION; HEMOPHILIA B; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTIC SYNDROME; PRIORITY JOURNAL; SKIN TEST;

ANAPHYLAXIS; CHILD, PRESCHOOL; FACTOR IX; HEMOPHILIA B; HUMANS; INFANT;

EID: 18844473466     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199701000-00003     Document Type: Article

References (22)

1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant FVIII in previously untreated subjects with hemophilia A: a 3.5 year observational study of safety, efficacy and inhibitor development. N Engl J Med 1993; 328: 453-9.
2. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
3. Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC II, eds. Inhibitors to coagulation factors. New York: Plenum Press, 1995: 35-45.
4. Briet E. Factor IX inhibitors in hemophilia B patients: their incidence and prospects for development with high purity factor IX products. Blood Coagul Fibrinolysis 1991; 2(suppl 1): 47-50.
5. High KA. Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC II, eds. Inhibitors to coagulation factors. New York: Plenum Press, 1995: 79-86.
6. Thompson AR. Molecular biology of the hemophilias. Prog Hemost Thromb 1991; 10: 175-214.
7. Ljung RC. Gene mutations and inhibitor formation in patients with haemophilia B. Acta Haematol 1995; 94(suppl 1): 49-52.
8. Green PM, Montandon AJ, Bentley DR, Giannelli F. Genetics and molecular biology of haemophilia A and B. Blood Coag Fibrinolysis 1991; 2: 539.
9. Matthews RJ, Anson DS, Peake IR, Bloom AL. Heterogeneity of the factor IX locus in nine hemophilia B inhibitor patients. J Clin Invest 1987; 79: 746.
10. Giannelli F, Green PM, High KA, et al. Haemophilia B: database of point mutations and short additions and deletions. Nucleic Acids Res 1993; 21: 3075.
11. Brandt MA, Sullivan TJ. Demonstration and characterization of human IgE and IgG antibodies to Factor VIII [Abstract 829, Q19]. J Allergy Clin Immunol 1992.
12. Rose NR, Friedman H, eds. Manual of clinical immunology. Washington, D.C.: American Society of Microbiologists, 1976.
13. Harper JL, Gill JC, Hopp RJ, et al. Induction of immune tolerance in a 7 year old hemophiliac with an anaphylactoid inhibitor. Thromb Haemost 1995; 74: 1039-41.
14. Department of Health and Human Services. Pilot study of hemophilia treatment in the U.S. Washington, D.C.: U.S. Government Printing Office, 1972. (National Heart and Lung Institute Blood Resource Studies, vol. 3).
15. Bove JR, McIntosh S. Anaphylactoid reaction to purified anti-hemophilic factor concentrate [Letter]. Transfusion 1988; 28: 603.
16. Schafer AI. Coagulation cascade: an overview. In: Loscalzo J, Schafer AI, eds. Thrombosis and hemorrhage. Cambridge, England: Blackwell Scientific Publishers, Inc.: 1994: 3-12.
17. Thorland EC, Lusher JM, Warrier I, et al. Hemophilia B patients with complete gene deletions have a very high risk for anaphylactic response to factor IX replacement therapy. Blood (in press).
18. Ketterling RP, Vielhaber EL, Lind TJ, Thorland EC, Sommer SS. The rates and patterns of deletions in the human factor IX gene. Am J Hum Genet 1994; 54: 201-13.
19. Bergmann F, Vester U, Rose M, Hoyer PF, Bohn U, Barthels M. Behandlungsaltervativen bei Hemmokörperhämophilie B: Erfahrungen mit dem Einsatz von rekombinatem Faktor VIIa (rVIIa). In: Scharrer I, Schramm W. Hämophilie-Symposium Hamburg 1993. Berlin, Heidelberg: Springer Verlag, 1994: 126-9.
20. Lenk H, Bierbach U, Schille R: Inhibitor to factor IX in haemophilia B and nephrotic syndrome in the course of immune tolerance treatment [Abstract no. 397]. Haemophilia 1996; 2(suppl 1): 104.
21. Pollmann H. A haemophilia B patient with complete factor IX gene deletion and a high titer antibody against FIX [Abstract 274]. Haemophilia 1996; 2(suppl 1): 72.
22. Ewenstein BM, Takemoto C, Warrier I, et al. Nephrotic syndrome as a complication of immune tolerances in Hemophilia B [letter] (submitted).